Skip to content
LPRO

Open Lending Corp

Open Lending Corp Q2 FY2024 earnings call

August 10, 2024 · fiscal period ended 2024-06

EPS · actual vs est

/

Revenue · actual vs est

/
Ask about this call

Summary

Generated 2024-08-10

Management highlights

  • Second quarter results were near or above guidance range for certified loans, revenue, and adjusted EBITDA, though impacted by a $6.7 million profit share change in estimate due to elevated delinquencies/defaults in 2021 - 2022 vintages. - Recent vintages show improved performance with tightened underwriting standards, including decreased 60 - plus day delinquency rates. - Market conditions: Automotive industry has improving inventory levels but new retail sales down; credit union customers face elevated loan - to - share ratios, low share/deposit growth, and low loan growth. - Product and technology: Working on solutions to improve lender and borrower experience, leveraging enhanced scorecard for targeted actions. - Added Securian Financial Group as insurance partner. - Taking measured approach to control costs, focusing on incremental costs driving near - term revenue growth.
View in transcript ↓

Segment performance

In the second quarter of 2024, Open Lending certified nearly 29,000 loans, representing approximately 3% sequential growth compared to Q1 2024. Total revenue was $26.7 million, with program fee revenues at $14.8 million, profit share revenues (net of a $6.7 million negative change in estimate) at $9.3 million, and claims administration fees and other revenue at $2.6 million. Adjusted EBITDA was $9.9 million. Operating expenses were $17 million, operating income was $4 million, net income was $2.9 million, and basic and diluted net income per share was $0.02.

View in transcript ↓

Guidance

Third quarter 2024 guidance: Total certified loans to be between $25,000 and $28,000, total revenue between $28 million and $31 million, and adjusted EBITDA between $11 million and $14 million. Considered factors like elevated interest rates, macroeconomic conditions, auto inventory and sales volumes, credit union lending capacity, and seasonality.

View in transcript ↓

Risks

  • Elevated delinquencies and defaults in 2021 - 2022 vintages as an industry - wide headwind. - Continued challenging macroeconomic conditions including elevated interest rates, uncertain job growth, and low credit union lending capacity. - Potential impact of interest rate fluctuations on consumer affordability and lending volume.
View in transcript ↓

Q&A highlights

Q: About CDK impact, could you quantify and if it self - corrected into July?

A: CDK outage impacted new auto vehicle sales more, had limited impact on used, and didn't affect Q2 volume and not expected to go forward on new much.

Q: Have you factored in a Fed rate cut in September in the guide and impact on refi?

A: Guidance has continued elevated rates, hopeful Fed cuts in September, and rate cuts could help refi channel.

Q: On profit share, any make whole period with financial partners?

A: No write checks for negative profit share, recapture comes back to carriers.

Q: On profit share adjustment, what's baked in and what causes downward adjustments?

A: Profit share has components like loss severity, default frequency, prepay speed. $6.7 million adjustment in Q2 was for '21 - '22 vintages, working through them as claim period is 18 - 24 months.

Q: Differentiate OEM certification volume vs bank and credit union volume in outlook?

A: Similar mix to Q2 between credit unions and OEMs.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS
Revenue

Transcript

August 10, 2024

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.